Natera (NTRA) Competitors $149.85 -8.33 (-5.27%) Closing price 04:00 PM EasternExtended Trading$150.39 +0.54 (+0.36%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NTRA vs. HIMS, GH, OPCH, RDNT, BTSG, SHC, SGRY, CON, PRVA, and WGSShould you be buying Natera stock or one of its competitors? The main competitors of Natera include Hims & Hers Health (HIMS), Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), and GeneDx (WGS). These companies are all part of the "healthcare" industry. Natera vs. Its Competitors Hims & Hers Health Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group GeneDx Natera (NASDAQ:NTRA) and Hims & Hers Health (NYSE:HIMS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do analysts prefer NTRA or HIMS? Natera presently has a consensus target price of $184.63, suggesting a potential upside of 23.21%. Hims & Hers Health has a consensus target price of $39.58, suggesting a potential downside of 21.53%. Given Natera's stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natera 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Hims & Hers Health 3 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92 Which has more volatility & risk, NTRA or HIMS? Natera has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Do insiders & institutionals believe in NTRA or HIMS? 99.9% of Natera shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 7.6% of Natera shares are held by insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is NTRA or HIMS more profitable? Hims & Hers Health has a net margin of 9.24% compared to Natera's net margin of -10.36%. Hims & Hers Health's return on equity of 22.75% beat Natera's return on equity.Company Net Margins Return on Equity Return on Assets Natera-10.36% -18.29% -11.68% Hims & Hers Health 9.24%22.75%15.51% Does the media favor NTRA or HIMS? In the previous week, Hims & Hers Health had 57 more articles in the media than Natera. MarketBeat recorded 71 mentions for Hims & Hers Health and 14 mentions for Natera. Natera's average media sentiment score of 1.33 beat Hims & Hers Health's score of 0.23 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 11 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Hims & Hers Health 16 Very Positive mention(s) 4 Positive mention(s) 44 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Which has better earnings & valuation, NTRA or HIMS? Hims & Hers Health has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatera$1.70B12.06-$190.43M-$1.47-101.94Hims & Hers Health$1.48B7.65$126.04M$0.6973.10 SummaryHims & Hers Health beats Natera on 9 of the 16 factors compared between the two stocks. Get Natera News Delivered to You Automatically Sign up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTRA vs. The Competition Export to ExcelMetricNateraMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.60B$7.11B$5.53B$9.30BDividend YieldN/A2.83%4.59%4.03%P/E Ratio-101.9434.4428.5619.60Price / Sales12.0629.22359.9473.66Price / CashN/A24.5224.7327.56Price / Book16.568.098.155.55Net Income-$190.43M$236.06M$3.24B$257.73M7 Day Performance-5.45%-2.33%2.03%0.95%1 Month Performance-9.37%0.45%8.29%10.68%1 Year Performance33.01%25.93%28.40%15.67% Natera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTRANatera1.6174 of 5 stars$149.85-5.3%$184.63+23.2%+41.7%$21.60B$1.70B-101.944,434News CoveragePositive NewsHIMSHims & Hers Health2.0733 of 5 stars$48.34+0.8%$39.58-18.1%+139.3%$10.82B$1.78B70.061,637Trending NewsAnalyst DowngradeInsider TradeGHGuardant Health4.5756 of 5 stars$49.54-1.9%$53.76+8.5%+60.2%$6.14B$739.02M-14.612,021News CoveragePositive NewsOPCHOption Care Health4.5113 of 5 stars$30.91-0.8%$35.50+14.8%+4.5%$5.06B$5.00B24.938,088Positive NewsRDNTRadNet3.9894 of 5 stars$55.26-1.7%$69.60+26.0%-7.8%$4.15B$1.83B-128.5111,021BTSGBrightSpring Health Services1.7671 of 5 stars$22.00-0.5%$24.90+13.2%+83.6%$3.87B$11.27B78.5735,000SHCSotera Health3.753 of 5 stars$11.40-3.0%$16.00+40.4%-6.1%$3.24B$1.11B142.523,000SGRYSurgery Partners2.5098 of 5 stars$22.03-0.5%$33.56+52.3%-16.4%$2.82B$3.11B-14.4015,000CONConcentra Group Holdings Parent2.8677 of 5 stars$20.33-1.1%$28.50+40.2%N/A$2.61B$1.90B15.1711,250PRVAPrivia Health Group3.9274 of 5 stars$21.35-3.4%$27.77+30.1%+16.6%$2.60B$1.74B177.931,140WGSGeneDx3.7759 of 5 stars$85.74-6.4%$90.13+5.1%+151.2%$2.45B$305.45M-60.811,200Analyst Downgrade Related Companies and Tools Related Companies HIMS Competitors GH Competitors OPCH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors CON Competitors PRVA Competitors WGS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTRA) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
